Professor Donald Singer
|
||
TITLEProfessor of Clinical Pharmacology & Therapeutics CONTACT
|
RESEARCH PROFILEVascular mechanisms important for prevention and treatment of cardiovascular disease. MD work concerned interactions between the renin-angiotensin system and the vaso-active and natriuretic family of cardiac peptides in blood pressure regulation and after heart transplantation. Interest in genetic mechanisms for cardiovascular disease has included studies of renal artery stenosis and of natriuretic peptide expression in the heart. Recent vascular biology studies include work on the capillary microcirculation in relation to hypertension and other cardiovascular disorders, exploring the role of oxidant stress in vascular dysfunction and the importance of CNP as a vascular paracrine factor. He also has a major interest in recognition and prevention of adverse drug reactions. He is currently leading a regional ADR policy initiative and is involved in developing a national and international multi-disciplinary network to explore ways to improve patient safety by imporving prevention of medication-related errors. Main research methods: Automated resting and ambulatory BP monitoring, classical organ bath pharmacology (MacLab data-capture), small artery myography (MacLab data-capture), forearm blood flow by venous occlusion plethysmography (MacLab data-capture), capillary videomicroscopy, vascular cell biology, molecular biology. |
RESEARCH GROUPS |
BACKGROUNDProfessor Donald Singer is foundation holder of the Chair of Clinical Pharmacology at the Medical School at Warwick University. He leads the Clinical Pharmacology Centre at the University Trust Walsgrave Hospital. He trained in Aberdeen and London, and before moving to Warwick in February 2003 ran research programmes at St George's Hospital Medical School, London and at Imperial College, London. His main research interests are in causes of vascular disease, better management of blood pressure and new systems to promote safety in prescribing, including applying pharmacogenetics to predicting risk of adverse drugs reactions. His initial major clinical aims at Warwick are establishing a Regional Hypertension Service and developing Adverse Drug Reaction Networks. He has an interest in Action Management as a way to bring together leadership and management skills from Public and Private Sectors. |
CURRENT RESEARCH PROJECTS
|
SELECTED PUBLICATIONS
|
|
|
RESEARCH DEGREES SUPERVISED
|
| Update My Profile on the Warwick eRA Portal | My Profile last updated: 02/08/2011 |
